Neurogenic Detrusor Overactivity Market Size to Exceed $2.45 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Neurogenic Detrusor Overactivity Market Grown from 2024 to 2025?
In the past few years, the market for neurogenic detrusor overactivity has seen significant growth. It is expected to expand from a size of $1.69 billion in 2024 to $1.82 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.9%. The expansion during the historic period can be linked to several factors. These include a growing number of neurological disorder cases, heightened awareness among healthcare professionals, increasing use of pharmaceutical remedies, development of hospital and clinic facilities, and a surge in the rates of diagnosis.
What Growth Rate Is Anticipated for the Neurogenic Detrusor Overactivity Market in the Coming Years?
The market size for neurogenic detrusor overactivity is projected to experience robust growth in the forthcoming years, expected to hit $2.45 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. This predicted growth during the forecast period is due to factors such as an increasing elderly population, a rise in occurrences of spinal cord injuries, heightened healthcare spending, broadening of minimally invasive treatment alternatives, and the elevation in patient knowledge and education. Key trends observed within the forecast period are advancements in stem cell methodologies, innovation in drug delivery systems, progression in neuromodulation devices, R&D in bespoke medicine, and advances in minimally invasive techniques.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp
Who Are the Leading Companies in the Neurogenic Detrusor Overactivity Market?
Major companies operating in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., Hugel Inc.
What Are the Key Drivers of the Neurogenic Detrusor Overactivity Market?
The neurogenic detrusor overactivity market is projected to expand due to the increasing prevalence of neurological disorders. These disorders, which impact the brain, nerves, or spinal cord, can lead to issues with cognition, sensation, movement, or other bodily functions. The rate of neurological disorders is on the rise as longevity increases, which ups the probability of age-associated cerebral deterioration. Neurogenic detrusor overactivity, commonly tied to neurological disorders such as Parkinson’s disease, multiple sclerosis, and spinal cord injuries, is a type of bladder malfunction. These ailments interrupt the normal nerve communication pathway from the brain to the bladder, which can result in involuntary bladder contractions. For example, a study published by the American Academy of Neurology (AAN) in April 2024 estimated that the global count of brain disorders will reach 4.9 billion cases by 2050, marking a 22% surge from the roughly 4 billion cases in 2021. Consequently, the escalating prevalence of neurological disorders is propelling the growth in the neurogenic detrusor overactivity market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24619&type=smp
What Are the Key Market Segments in the Neurogenic Detrusor Overactivity Industry?
The neurogenic detrusor overactivity market covered in this report is segmented –
1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
2) By Application: Adult, Child
3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
Subsegments:
1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
What Are the Latest Trends in the Neurogenic Detrusor Overactivity Market?
Companies leading the neurogenic detrusor overactivity (NDO) treatment market are pouring their resources into the development of advanced generic therapies like beta-3 adrenergic receptor agonists, in a bid to provide cost-effective bladder control remedies. This class of medicines, including mirabegron, work by relaxing the bladder’s detrusor muscle which ultimately expands the bladder’s capacity while diminishing such symptoms as urgency and incontinence. For example, in April 2024, the U.S. Food and Drug Administration (USFDA) gave its approval to Lupin Ltd., a pharmaceutical firm based in India, for the introduction of Mirabegron, the generic counterpart of Myrbetriq, into the U.S. market. Mirabegron, which is a progressive, once-daily, oral therapy, presents a practical and efficient treatment alternative for overactive bladder (OAB) and NDO within paediatric demographics. This endorsement from the USFDA further strengthens Lupin Ltd.’s dedication towards widening the availability of affordable, top-quality generic medicines in essential therapeutic fields.
Access The Full Report Here:
What Are the Key Regional Markets in the Neurogenic Detrusor Overactivity Industry?
North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24619
This Report Delivers Insight On:
1. How big is the neurogenic detrusor overactivity market, and how is it changing globally?
2. Who are the major companies in the neurogenic detrusor overactivity market, and how are they performing?
3. What are the key opportunities and risks in the neurogenic detrusor overactivity market right now?
4. Which products or customer segments are growing the most in the neurogenic detrusor overactivity market?
5. What factors are helping or slowing down the growth of the neurogenic detrusor overactivity market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
